60 related articles for article (PubMed ID: 24216091)
1. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
[TBL] [Abstract][Full Text] [Related]
2. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy.
Budipramana K; Sangande F
Chem Biol Drug Des; 2024 May; 103(5):e14534. PubMed ID: 38697951
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in c-Met-based dual inhibitors in the treatment of cancers.
Jin F; Lin Y; Yuan W; Wu S; Yang M; Ding S; Liu J; Chen Y
Eur J Med Chem; 2024 Jun; 272():116477. PubMed ID: 38733884
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anti-tumor activity evaluation of 1H-pyrrolo[2,3-b]pyridine-2-carboxamide derivatives with phenyl sulfonamide groups as potent RSK2 inhibitors.
Zhang X; Zheng G; Gao S; Zhou F; Pan T; Shi Q; Li J; Zhang X; Huang Z; Quan X
Chem Biol Drug Des; 2024 Jan; 103(1):e14376. PubMed ID: 37852922
[TBL] [Abstract][Full Text] [Related]
5. Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.
Henderson SH; Sorrell FJ; Bennett JM; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Navratilova IH; Elkins JM; Ward SE
Eur J Med Chem; 2024 Apr; 269():116292. PubMed ID: 38479168
[TBL] [Abstract][Full Text] [Related]
6. Imidazo[1,2-A]Pyridine: Potent Biological Activity, SAR and Docking In-vestigations (2017-2022).
Narayan A; Patel S; B Baile S; Jain S; Sharma S
Infect Disord Drug Targets; 2024 Mar; ():. PubMed ID: 38509674
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, antitumor activity and NMR-based metabolomics of novel amino substituted tetracyclic imidazo[4,5-b]pyridine derivatives.
Perin N; Lončar B; Kadić M; Kralj M; Starčević K; A Carvahlo R; Jarak I; Hranjec M
ChemMedChem; 2024 May; ():e202300633. PubMed ID: 38757872
[TBL] [Abstract][Full Text] [Related]
8. Discovery of imidazo[1,2-
Akwata D; Kempen AL; Lamptey J; Dayal N; Brauer NR; Sintim HO
RSC Med Chem; 2024 Jan; 15(1):178-192. PubMed ID: 38283221
[TBL] [Abstract][Full Text] [Related]
9. Gold Catalysed Redox Synthesis of Imidazo[1,2-
Talbot EP; Richardson M; McKenna JM; Toste FD
Adv Synth Catal; 2014 Mar; 356(4):687-691. PubMed ID: 24839436
[TBL] [Abstract][Full Text] [Related]
10. Novel mono substituted pyridoimidazoisoquinoliniums
Kawakubo M; Inoh Y; Murata Y; Matsumura M; Furuno T; Yasuike S
RSC Adv; 2024 Mar; 14(14):9758-9762. PubMed ID: 38525055
[TBL] [Abstract][Full Text] [Related]
11. Applications of palladium-catalyzed C-N cross-coupling reactions in pharmaceutical compounds.
Emadi R; Bahrami Nekoo A; Molaverdi F; Khorsandi Z; Sheibani R; Sadeghi-Aliabadi H
RSC Adv; 2023 Jun; 13(27):18715-18733. PubMed ID: 37346956
[TBL] [Abstract][Full Text] [Related]
12. Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition.
Damghani T; Elyasi M; Pirhadi S; Haghighijoo Z; Ghazi S
Mol Divers; 2022 Jun; 26(3):1411-1423. PubMed ID: 34247323
[TBL] [Abstract][Full Text] [Related]
13. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
Ahmed MF; Santali EY; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
[TBL] [Abstract][Full Text] [Related]
14. Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles.
Cheuka PM; Lawrence N; Taylor D; Wittlin S; Chibale K
Medchemcomm; 2018 Oct; 9(10):1733-1745. PubMed ID: 30429978
[TBL] [Abstract][Full Text] [Related]
15. Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents.
Wang J; Zhang L; Pan X; Dai B; Sun Y; Li C; Zhang J
Sci Rep; 2017 Mar; 7():45145. PubMed ID: 28332573
[TBL] [Abstract][Full Text] [Related]
16. Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions.
Ruiz-Castillo P; Buchwald SL
Chem Rev; 2016 Oct; 116(19):12564-12649. PubMed ID: 27689804
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups.
Jiang Y; Zhang K; Gao S; Wang G; Huang J; Wang J; Chen L
Molecules; 2016 May; 21(5):. PubMed ID: 27187326
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold.
Zhang W; Ai J; Shi D; Peng X; Ji Y; Liu J; Geng M; Li Y
Molecules; 2014 Feb; 19(2):2655-73. PubMed ID: 24566328
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
